Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia.
Matthew G CyrMaissa MhibikJunpeng QiHaiyong PengJing ChangErika M GaglioneDavid EikJohn HerrickThomas VenablesScott J NovickValentine V CouroublePatrick R GriffinAdrian WiestnerChristoph RaderPublished in: Journal for immunotherapy of cancer (2022)
NCT00923507.